Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7280423 | Brain, Behavior, and Immunity | 2016 | 38 Pages |
Abstract
Together, these results suggest that TAK-242 is a TLR4 antagonist that has efficacy after systemic and intrathecal delivery and confirms the role of endogenous TLR4 signaling in triggering the development of a delayed allodynia in both male and female mice.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sarah A. Woller, Satheesh B. Ravula, Fabio C. Tucci, Graham Beaton, Maripat Corr, R. Rivkah Isseroff, Athena M. Soulika, Marianne Chigbrow, Kelly A. Eddinger, Tony L. Yaksh,